Serum oncostatin M, a potential biomarker of disease activity and infliximab response in IBD patients: Study

The results highlighted that;

• CLIA approach demonstrated excellent analytical performance, with a broad linear range of 31.25-25000 pg/mL, a low detection limit of 23.2 pg/mL, acceptable precision, and appropriate accuracy.
• Serum OSM levels were greater in IBD and non-IBD patients than in healthy controls.
• Serum OSM levels were higher in moderate and severe patients compared to those in remission, according to a study of clinical and endoscopic activity.
• IBD patients who did not repair their mucosa exhibited greater serum OSM levels than those who did heal their mucosa. Furthermore, serum OSM levels were higher in clinical non-responders than in responders, indicating a high recognition capacity with an AUC of 0.898.

In conclusion, the authors added, "The newly created CLIA approach demonstrated considerable potential for usage in the clinic. In IBD patients, elevated serum OSM expression was a potential indicator of severe illness and infliximab non-response."

Reference:

Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, Wang X, Yu P, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem. 2021 Nov 26:S0009-9120(21)00310-6. doi: 10.1016/j.clinbiochem.2021.11.011.